You are here: Industry Insights > Market News

News List

Interview – German Merck doubles down on dual-acting cancer agents epvantage
June 13, 2017
German Merck doubles down on dual-acting cancer agents
Aptar Pharma extends nasal pump manufacturing capabilities in US europeanpharmaceuticalreview
June 13, 2017
Aptar Pharma has announced the installation of manufacturing capacity for its child-resistant and Senior-Friendly Classic Nasal Pump in their Congers, NY site.
What does a hung parliament mean for UK healthcare? europeanpharmaceuticalreview
June 13, 2017
Hitesh Dodhia, Superintendent Pharmacist at Pharmacy Outlet, discusses the announcement of a hung parliament and what it means for UK healthcare…
Adherium appoints new CEO to drive global growth biospectrumasia
June 13, 2017
He has also served as Director of Product Development at Delphi Medical Systems
New leukemia treatment outperforms standard chemotherapies biospectrumasia
June 13, 2017
Around 1,000 people are diagnosed with AML in Australia each year and, depending on the patient's age, there is a high rate of mortality with only about 30 percent surviving long term
Tresiba® Demonstrated No Increased Risk Of Major Cardiovascular Events and Significant Reduction in en-cphi.cn
June 13, 2017
Novo Nordisk today announced the primary results from DEVOTE - the first randomised, double-blind, treat-to-target, event-driven trial comparing two basal insulins, Tresiba® (insulin degludec injection 100 U/mL) and insulin glargine U100...
mindBEAGLE: The first EEG-based BCI System Ever for Communication with Complete Locked-in Patients en-cphi.cn
June 13, 2017
Frontiers in Neuroscience recently published an article presenting mindBEAGLE as the very first and only EEG-based Brain-Computer Interface (BCI) that enables communication with patients who suffer from locked-in syndrome (LIS)...
Top 10 diabetes drugs by 2016 sales fiercepharma
June 13, 2017
To say there’s a lot going on in the U.S. diabetes space right now would be an understatement.
FDA Requests Removal of Opana ER for Risks Related To Abuse americanpharmaceuticalreview
June 12, 2017
The U.S. Food and Drug Administration requested that Endo Pharmaceuticals remove its opioid pain medication, reformulated Opana ER (oxymorphone hydrochloride), from the market. After careful consideration, the agency is seeking removal based on its concer
FDA makes unprecedented move, asks Endo to pull painkiller from market pharmaphorum
June 12, 2017
The FDA has asked Endo to voluntarily remove its painkiller Opana ER from the US market, because of concerns it is fuelling the country’s opioid addiction epidemic.